Balloons are as good as stents, but it can be hard to get cardiologists to change their habits.
Over industry objections, a Medicare panel endorses patient symptom reporting tools that could lower payments for drugs with a high side-effect burden.
To determine whether Medicare covers CAR-T it might soon be important to find out how patients feel.
Pharma sector pushes back against a programme that mandates cheaper prices for hospitals serving the poor.
Biopharma might be getting the pricing controls that it tried to stop.
If investors have visions of Luxturna-like prices they might need to blink and look again.
Medicare Advantage plans have been cleared to seek cheaper alternatives for biologicals beginning next year.
Private price negotiation is a hallmark of the US health care system – banning rebates does not make that any less true.
As drug prices climb, is it time to ask whether the landmark technology transfer law is a fair deal for US taxpayers?